Status:

RECRUITING

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Lead Sponsor:

Vanderbilt University Medical Center

Collaborating Sponsors:

American Heart Association

Conditions:

Post-acute COVID-19 Syndrome

Postural Tachycardia Syndrome (POTS)

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections. This syndrome affects mostly women (\~80%)...

Detailed Description

Post-acute sequelae of COVID-19 infection or Long COVID is a growing concern, even in patients with mild initial illness. These patients develop numerous chronic debilitating symptoms including fatigu...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Prior RT-PCR-confirmed COVID-19 infection.
  • Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms.
  • Exclusion criteria:
  • Heart Disease: Myocardial Infarction, angina, heart failure
  • History of stroke, or transient ischemic attack
  • Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries)
  • Uncontrolled hypertension defined as persistent blood pressure \>140/90.
  • Post-menopausal women.
  • Diabetes Mellitus Type 1 or Type 2. ,
  • Impaired Hepatic function
  • Impaired renal function test (eGFR\<60 mL/min/1.73m2).
  • Ongoing substance abuse.
  • Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study.
  • History of seizures.
  • Chronic use of steroids, NSAIDs.
  • On biologics such as anti-IL6 (omalizumab) and anti-TNF-alpha drugs
  • Pregnancy or breastfeeding

Exclusion

    Key Trial Info

    Start Date :

    June 1 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2026

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT05421208

    Start Date

    June 1 2022

    End Date

    December 1 2026

    Last Update

    July 15 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Vanderbilt University Medical Center

    Nashville, Tennessee, United States, 37232